Q-omics provides the consensus-scored MTCO1P14 profile across patient tissues and cancer cell-line models. MTCO1P14 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, MTCO1P14 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, MTCO1P14 RNA expression shows 5,148 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight LUSC, HNSC, and LAML as cancer lineages where MTCO1P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO1P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO1P14 survival associations across molecular data types. MTCO1P14 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO1P14 RNA expression–survival associations across cancer types. High MTCO1P14 expression shows unfavorable associations in LUSC, MESO, DLBC and BRCA, but favorable associations in ACC and ESCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for MTCO1P14 RNA expression.
This table summarizes MTCO1P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO1P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO1P14 shows lower tumor expression in HNSC and KIRC and higher tumor expression in PRAD. The HNSC box plot shows higher MTCO1P14 RNA expression in normal versus tumor tissue (log2 FC = −0.016, t-test p = .002).
This table shows molecular features associated with MTCO1P14 in patient tissues and cancer cell lines. In patient samples, MTCO1P14 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
